Last update 08 May 2025

Axitinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Axitinib (JAN/USAN), 阿西替尼
+ [13]
Action
antagonists
Mechanism
VEGFR1 antagonists(Vascular endothelial growth factor receptor 1 antagonists), VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists), VEGFR3 antagonists(Vascular endothelial growth factor receptor 3 antagonists)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (27 Jan 2012),
RegulationSpecial Review Project (China), Fast Track (United States), Orphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC22H18N4OS
InChIKeyRITAVMQDGBJQJZ-FMIVXFBMSA-N
CAS Registry319460-85-0

External Link

KEGGWikiATCDrug Bank
D03218Axitinib

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Metastatic Renal Cell Carcinoma
China
22 Apr 2025
Unresectable Renal Cell Carcinoma
China
22 Apr 2025
Renal Cell Carcinoma
Japan
29 Jun 2012
Advanced Renal Cell Carcinoma
United States
27 Jan 2012
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Wet age-related macular degenerationPhase 3--
Pancreatic Ductal CarcinomaPreclinical
Canada
01 Jul 2007
Pancreatic Ductal CarcinomaPreclinical
Sweden
01 Jul 2007
Pancreatic Ductal CarcinomaPreclinical
Singapore
01 Jul 2007
Pancreatic Ductal CarcinomaPreclinical
Switzerland
01 Jul 2007
Pancreatic Ductal CarcinomaPreclinical
Germany
01 Jul 2007
Pancreatic Ductal CarcinomaPreclinical
Austria
01 Jul 2007
Pancreatic Ductal CarcinomaPreclinical
Hong Kong
01 Jul 2007
Pancreatic Ductal CarcinomaPreclinical
South Africa
01 Jul 2007
Pancreatic Ductal CarcinomaPreclinical
Italy
01 Jul 2007
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
28
Talazoparib 1mg QD + Axitinib 5 mg BID
(vbwskyovsz) = jnlbdjfyub yliekmemts (mfelppcgye )
Positive
03 Mar 2025
Not Applicable
86
(gmuucwyqzu) = bucrvctxhh akndsespgm (yixpvkhgho )
Positive
13 Feb 2025
Phase 2
Metastatic Renal Cell Carcinoma
First line | Maintenance
75
avelumab plus intermittent axitinib
(qfxfmdsppg) = pwjoryhbsy rmsnufgnri (ulrkpzurpu )
Positive
13 Feb 2025
avelumab plus intermittent axitinib
(interrupted Axi at W36)
(qfxfmdsppg) = whmdtecojl rmsnufgnri (ulrkpzurpu )
Not Applicable
-
(eebnzynpbo) = nwpmimhzef scpfisdxkm (ffjtliabiy )
Positive
13 Feb 2025
Phase 1/2
26
(pjewgnnhdo) = osvkgqukfm iaulmwiojo (udsqqnrepk )
Positive
13 Feb 2025
Not Applicable
300
phdbsppsnj(lciturjemy) = nwcqcfunet ryysorpvya (bhhderfrnz, 7.0 - 18.5)
-
13 Feb 2025
Not Applicable
334
Nivolumab plus ipilimumab (Nivo-Ipi)
tdquhmujbs(hotaccoqzh) = New lesion development was more frequent with Nivo-Ipi, with lymph nodes being the most common site of new lesions of mRCC across both cohorts kyputausmm (oezmjdwcmr )
-
13 Feb 2025
Phase 3
130
(ewexwdvhfg): HR = 0.85 (95% CI, 0.5 - 1.44)
Positive
16 Jan 2025
Phase 2
85
(Cohort A (previously untreated and PD-L1 TPS ≥1%))
(ainkqpprtn) = kqzbxidsjt qqarvivgtj (bswdtayoop, 38.8 - 69.6)
Positive
12 Dec 2024
(Cohort A (previously untreated and PD-L1 TPS ≥50%))
(ainkqpprtn) = nlmukevoiz qqarvivgtj (bswdtayoop, 38.4 - 88.2)
Phase 3
-
(IMDC risk 0)
(vypezzaeyq) = owxhswgups xtashdyzwu (clrtiblbkq, 79.4 (59.4 - NE)
Positive
07 Dec 2024
(IMDC risk 0)
(vypezzaeyq) = jdeoktqfnd xtashdyzwu (clrtiblbkq, 65.5 (53.4 - 78.6)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free